Product logins

Find logins to all Clarivate products below.


Blog

Here you will find relevant articles and insight into all Clarivate related products and news.

Featured posts

Six companies enabling precision interventions for “undruggable” targets Six companies enabling precision interventions for “undruggable” targets
Blog October 7, 2025
Six companies enabling precision interventions for “undruggable” targets
GLP-1 weight loss access comes down to a dogfight in the U.S. GLP-1 weight loss access comes down to a dogfight in the U.S.
Blog October 3, 2025
GLP-1 weight loss access comes down to a dogfight in the U.S.
chevron_left
chevron_right
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Biopharma Biotech Clinical trials
Relacorilant:  when evidence meets the established evidence bar Relacorilant:  when evidence meets the established evidence bar
Blog February 24, 2026
Relacorilant: when evidence meets the established evidence bar
Biopharma Biotech Clinical trials
Tolebrutinib: when safety concerns override efficacy signals Tolebrutinib: when safety concerns override efficacy signals
Blog February 24, 2026
Tolebrutinib: when safety concerns override efficacy signals
Biopharma Biotech Clinical trials
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Blog February 24, 2026
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Biopharma Biotech Clinical trials
Key market access considerations for long-acting and alternative delivery therapies Key market access considerations for long-acting and alternative delivery therapies
Blog February 20, 2026
Key market access considerations for long-acting and alternative delivery therapies
Biopharma Commercialization FDA
The market access “sweet spots” where payers reimburse more convenient therapies The market access “sweet spots” where payers reimburse more convenient therapies
Blog February 19, 2026
The market access “sweet spots” where payers reimburse more convenient therapies
Biopharma Commercialization FDA
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization
What healthcare payers reward: adherence versus outcomes What healthcare payers reward: adherence versus outcomes
Blog February 2, 2026
What healthcare payers reward: adherence versus outcomes
Biopharma HMO IDN